EUVIMEDEUVIMED entdecken
Crossref

Immune Checkpoint Inhibitor Therapy in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma: A Narrative Review

Jacqueline Jiang, Alvin H. Chong, Luke S. McLean

Australasian Journal of Dermatology · 18.11.2026

DOI: 10.1111/ajd.70238 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Australasian Journal of Dermatology, online erschienen am 18.11.2026. Verfasst von Jacqueline Jiang und 2 weiteren Autor:innen. Die Arbeit nennt 40 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cutaneous squamous cell carcinoma (cSCC) is a leading cause of cancer‐related morbidity and mortality in solid organ transplant recipients (SOTRs). Immune checkpoint inhibitors (ICIs) targeting programmed death receptor‐1 (PD‐1) have transformed the management of advanced cSCC, but SOTRs were excluded from the pivotal registrational trials. Early evidence of ICIs in this population was confined to retrospective studies, in which allograft rejection occurred in up to 42% of patients. However, retrospective studies were confounded by variable practice with immunosuppression regimes and concurrent ICI administration, both of which could independently contribute to rejection. This review synthesises the retrospective literature, the prospective trials designed to identify a protocol for ICI use in SOTRs with advanced cSCC, and contextualises the implications to clinical practice. While there remains a paucity of prospective trial data, two approaches show promise for preserving ICI‐mediated anti‐tumour efficacy with lower rejection rates than reported in retrospective studies. The current evidence supports consideration of ICIs in kidney transplant recipients with advanced cSCC with multidisciplinary input from dermatology, medical oncology and transplant physicians. Decision‐making should account for tumour stage, prior therapy, immunological risk profile and patient preferences, with pre‐treatment counselling regarding the risks and benefits, and contingency planning for dialysis in the event of allograft loss.

Zitieren

APA

Jiang, J., Chong, A. H., & McLean, L. S. (2026). Immune Checkpoint Inhibitor Therapy in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma: A Narrative Review. Australasian Journal of Dermatology. https://doi.org/10.1111/ajd.70238

Vancouver

Jiang J, Chong AH, McLean LS. Immune Checkpoint Inhibitor Therapy in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma: A Narrative Review. Australasian Journal of Dermatology. 2026. doi:10.1111/ajd.70238

BibTeX
@article{Jiang2026,
  author = {Jiang, Jacqueline and Chong, Alvin H. and McLean, Luke S.},
  title = {Immune Checkpoint Inhibitor Therapy in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma: A Narrative Review},
  journal = {Australasian Journal of Dermatology},
  year = {2026},
  doi = {10.1111/ajd.70238}
}
Kostenlos starten →